Clover reports positive Phase 2 respiratory combination vaccine trial in adults
Clover Biopharmaceuticals announced positive Phase 2 clinical trial results in Australia for its combination vaccine candidates targeting respiratory syncytial virus and human metapneumovirus in older adults
Clover Biopharmaceuticals, Ltd. announced positive Phase 2 trial results for their protein-based RSV+hMPV±PIV3 respiratory vaccine candidates in older adults. The trial, conducted in Australia, involved 420 participants aged 60-85 years and showed antibody titers and neutralizing antibody increases in line with or higher than previous trials.
The addition of PIV3 (PIV3) antigen in the triple vaccine (SCB-1033) did not reduce the effectiveness of the RSV+hMPV component. The vaccine showed no significant side effects and was generally well-tolerated with mild local and systemic adverse events. Clover's Trimer-Tag technology platform for multi-valent protein-based vaccines was validated in this study.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
